Pipeline
Sensei is developing a pipeline of investigational medicines that have potential to alter the relationship between host immune cells and cancer so that the immune system recognizes tumors as a threat and unleashes an immune response.
TMAb™ Programs
The TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Our current pipeline candidates are designed to be active only within the low-pH tumor microenvironment.
*Sensei has entered into a clinical supply agreement with Regeneron supporting the planned evaluation of SNS-101 in combination with Regeneron’s anti-PD-1 therapy Libtayo®️ (cemiplimab) in a Phase 1/2 clinical trial in solid tumors.